Drug Trial Radar · NCT01907087
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease
Last checked: Nov 20, 2026Latest source record: Mar 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 2013
Primary completion
Nov 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jul 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether BMN 190 is safe and effective in the treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease.
Conditions
- Jansky-Bielschowsky Disease
- Batten Disease
- Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
- CLN2 Disease
Interventions
BMN 190Biological
30-300 mg ICV infusion administered every other week for at least 48 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Motor-Language (ML) Scale Score During 300 mg Dosing PeriodTime frame: Baseline, Week 49/Last Assessment
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Nationwide Children's Hospital
Columbus, Ohio
University Hamburg-Eppendorf
Hamburg, Germany
Bambino Gesù Children's Hospital
Rome, Italy
Guy's & St. Thomas NHS Foundation Trust
London, United Kingdom
Great Ormond Street Hospital for NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.